Sunshine Biopharma, Inc.
NASDAQ: SBFMW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Steve N. Slilaty
- Employees
- 52
- Headquarters
- Pointe-Claire, Canada
- IPO year
- 2022
- Market cap
- $250.3K
- Website
- https://www.sunshinebiopharma.com
Loading SBFMW…
Loading profile data…Frequently asked questions about SBFMW
What does Sunshine Biopharma, Inc. (SBFMW) do?
Sunshine Biopharma, Inc. operates as a pharmaceutical and nutritional supplement company primarily dedicated to the research and development of innovative anticancer drugs. The company's pipeline includes Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin. This compound is currently in development to address a broad spectrum...
Where does SBFMW trade?
Sunshine Biopharma, Inc. (SBFMW) trades on the NASDAQ Capital Market.
What sector is SBFMW in?
Sunshine Biopharma, Inc. (SBFMW) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Sunshine Biopharma, Inc.?
Steve N. Slilaty is the chief executive officer of Sunshine Biopharma, Inc. (SBFMW).
Where is Sunshine Biopharma, Inc. headquartered?
Sunshine Biopharma, Inc. is headquartered in Canada.
Does SBFMW pay a dividend?
Sunshine Biopharma, Inc. (SBFMW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SBFMW go public?
Sunshine Biopharma, Inc. (SBFMW) completed its initial public offering in 2022.